Semaglutide for Weight Loss: What You Need to Know Before Starting

How Semaglutide Works: The GLP-1 Mechanism Explained

To understand why semaglutide is so effective for weight loss, you need to understand the role of GLP-1 in your body. Glucagon-like peptide-1 (GLP-1) is a hormone naturally produced in the intestines after you eat. It performs several functions: it signals the pancreas to release insulin, tells the liver to reduce glucose production, slows the speed at which food leaves your stomach (gastric emptying), and communicates with appetite-regulating centers in the brain.

Natural GLP-1 has a very short half-life. Your body breaks it down within minutes, which limits its impact. Semaglutide is a modified version of GLP-1 that has been engineered to resist degradation, giving it a half-life of approximately 7 days. This extended duration is what allows it to be administered as a once-weekly injection.

The weight loss effects of semaglutide stem primarily from three mechanisms working in concert. First, it reduces appetite at the neurological level by acting on GLP-1 receptors in the hypothalamus, the brain region that regulates hunger and satiety. Patients consistently report feeling less hungry, having fewer food cravings, and feeling satisfied with smaller portions. Second, semaglutide slows gastric emptying, meaning food stays in your stomach longer after meals. This prolongs the sensation of fullness and naturally reduces caloric intake. Third, it improves insulin sensitivity and glucose metabolism, which can reduce the metabolic dysfunction that makes weight loss difficult for many patients.

Importantly, semaglutide does not suppress appetite through stimulant effects (like phentermine) or by altering serotonin pathways (like older weight loss drugs). The GLP-1 mechanism works through the same hormonal pathways your body already uses to regulate hunger, which is why the appetite reduction tends to feel natural rather than forced.

Clinical Trial Results: What the Data Shows

The evidence base for semaglutide's weight loss efficacy is among the strongest of any medication in this category. The STEP (Semaglutide Treatment Effect in People with obesity) trial program included four major studies that evaluated semaglutide 2.4 mg weekly in different patient populations.

These results are clinically meaningful. For a 220-pound patient, a 15 percent body weight loss translates to approximately 33 pounds. More importantly, the weight loss was associated with improvements in cardiometabolic risk factors including blood pressure, waist circumference, lipid profiles, and inflammatory markers.

The STEP 4 trial is particularly instructive because it demonstrates what happens when patients stop taking semaglutide. Participants who switched to placebo after 20 weeks of treatment regained approximately two-thirds of the weight they had lost, underscoring the chronic nature of obesity and the potential need for ongoing treatment.

Semaglutide vs Tirzepatide: How They Compare

Tirzepatide (brand name Mounjaro for diabetes, Zepbound for weight loss) is a newer medication that has entered the weight loss conversation. While semaglutide targets only GLP-1 receptors, tirzepatide is a dual agonist that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism appears to produce greater weight loss in head-to-head comparisons.

While tirzepatide appears to produce greater average weight loss, the choice between the two medications is not solely based on efficacy numbers. Individual response varies considerably, and some patients may respond better to one medication than the other. Factors such as insurance coverage, availability, side effect tolerance, and cost all play a role in the decision. Your provider can help determine which medication is the best starting point based on your clinical profile.

Dose Escalation Schedule

Semaglutide is not started at full dose. A gradual escalation protocol is used to minimize gastrointestinal side effects and allow your body to adjust. Each dose level is maintained for 4 weeks before increasing.

This gradual approach is important. Patients who skip the escalation or increase doses too quickly are significantly more likely to experience severe nausea, vomiting, and other gastrointestinal side effects that may lead them to discontinue treatment entirely. In our clinical experience, patients who follow the escalation schedule faithfully tend to tolerate the medication well and achieve better long-term adherence.

Some patients achieve satisfactory weight loss at intermediate doses (1.0 or 1.7 mg) and may not need to escalate to the full 2.4 mg dose. This is a clinical decision that should be made in collaboration with your provider based on your progress, side effects, and goals.

What to Expect Month by Month

Understanding the typical timeline helps set realistic expectations. Individual results vary, but the following month-by-month breakdown reflects what most patients experience in a medically supervised program.

Month 1 (0.25 mg): This is the adjustment period. Weight loss during the first month is typically modest, ranging from 2 to 5 pounds. Some patients notice reduced appetite, while others feel little change at this starting dose. Mild nausea is common in the first week or two and typically improves as your body adapts. Focus during this month should be on establishing healthy eating patterns and staying hydrated.

Month 2 (0.5 mg): Appetite reduction becomes more noticeable. Most patients find they are naturally eating smaller portions and experiencing fewer cravings, particularly for high-calorie foods. Weight loss typically accelerates to 3 to 6 pounds this month. This is when many patients begin to see the medication's effect on their relationship with food.

Month 3 (1.0 mg): Significant appetite suppression is now well established. Total weight loss from baseline is typically 8 to 15 pounds. Energy levels often improve as excess weight decreases and metabolic function improves. Patients who have started or maintained exercise programs may notice improved endurance and body composition changes.

Month 4 (1.7 mg): Weight loss continues at a steady pace, typically 3 to 5 pounds per month. Total weight loss from baseline may reach 15 to 22 pounds. Patients often notice improvements in blood pressure, energy, joint comfort, and clothing fit. Lab values (glucose, cholesterol, triglycerides) frequently show measurable improvement by this point.

Month 5 to 6 (2.4 mg): At full maintenance dose, weight loss continues but may begin to slow as the body approaches a new set point. Total weight loss from baseline typically reaches 20 to 35 pounds (10 to 17 percent of starting body weight). This is also when the importance of complementary lifestyle habits becomes most apparent. Patients who have adopted sustainable nutrition and exercise practices tend to see continued progress, while those relying solely on the medication may plateau.

Month 6 and beyond: Weight loss may continue at a slower pace through month 12 and even beyond. The focus shifts toward weight maintenance and sustaining the metabolic improvements achieved. Regular follow-up with your provider ensures that dosing remains appropriate and that any emerging concerns are addressed promptly.

Common Side Effects and How to Manage Them

Gastrointestinal side effects are the most commonly reported adverse effects of semaglutide. Understanding what to expect and how to manage these effects can make the difference between a successful treatment course and premature discontinuation.

Nausea: The most common side effect, reported by approximately 44 percent of patients in clinical trials. It is typically most pronounced during the first 1 to 2 weeks of each dose escalation and tends to improve with continued use. Eating smaller, more frequent meals, avoiding high-fat and greasy foods, staying well hydrated, and eating slowly can all help reduce nausea. Ginger tea or ginger supplements may provide additional relief.

Constipation: Reported by approximately 24 percent of patients. Adequate hydration (at least 64 ounces of water daily), fiber-rich foods, regular physical activity, and over-the-counter fiber supplements can help maintain regularity. If constipation becomes persistent, your provider may recommend additional interventions.

Diarrhea: Less common than nausea and constipation, but reported by approximately 18 percent of patients. It is typically self-limiting and resolves within the first few weeks of a new dose level.

Fatigue: Some patients report tiredness, particularly during the early weeks of treatment. This may be related to reduced caloric intake as appetite decreases. Ensuring adequate protein intake (at least 0.7 to 1.0 grams per pound of lean body mass) and avoiding severely low-calorie diets can help maintain energy levels.

Injection site reactions: Mild redness, swelling, or itching at the injection site is occasionally reported. Rotating injection sites between the abdomen, thigh, and upper arm can minimize this.

More serious but rare side effects include pancreatitis, gallbladder disease, and potential thyroid effects. Any persistent abdominal pain, severe vomiting, or other concerning symptoms should be reported to your provider immediately.

Who Is a Candidate for Semaglutide?

Semaglutide for weight loss is not appropriate for everyone. Understanding the clinical criteria can help you determine whether this medication may be an option for you.

The FDA-approved criteria for semaglutide (Wegovy) include adults with a BMI of 30 or greater (obesity), or adults with a BMI of 27 or greater (overweight) who have at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea.

Beyond BMI criteria, ideal candidates are patients who have attempted lifestyle modifications (diet, exercise) without achieving adequate or sustained weight loss. Semaglutide is designed to complement these efforts, not replace them. Patients who are motivated to make dietary changes and increase physical activity while on the medication tend to achieve the best and most durable results.

Why Medical Supervision Matters

The rise of online prescribers and telehealth-only weight loss clinics has made semaglutide more accessible, but accessibility without proper oversight carries real risks. Here is why a medically supervised program provides meaningfully better care.

Comprehensive health evaluation: A qualified provider will evaluate your full medical history, current medications, and existing health conditions before prescribing. Semaglutide interacts with several medication classes and is contraindicated in certain conditions. An online questionnaire cannot substitute for a clinical evaluation.

Lab monitoring: Baseline and ongoing lab work is important for tracking metabolic improvements, identifying early signs of complications (such as gallbladder dysfunction or pancreatic inflammation), and adjusting treatment as your body changes. Providers who prescribe without lab monitoring are missing critical safety data.

Nutritional guidance: Semaglutide reduces appetite, but it does not teach you how to eat. Without nutritional guidance, patients may inadvertently develop nutrient deficiencies, lose muscle mass due to inadequate protein intake, or fail to establish the eating patterns needed for long-term weight maintenance.

Dose management: The escalation schedule is a guideline, not a rigid protocol. Some patients benefit from slower escalation, extended time at intermediate doses, or dose reduction if side effects are intolerable. A provider who knows your history can make these adjustments intelligently.

Transition planning: What happens when you stop the medication? A good medical weight loss program addresses this question from the beginning, building sustainable habits and considering maintenance strategies that reduce the risk of weight regain.

At Allen Medical Aesthetics, our weight loss program integrates semaglutide (and tirzepatide) prescribing with nutritional counseling, body composition monitoring, lab work, and ongoing provider support. We believe that the medication is most effective when it is part of a comprehensive strategy, not when it stands alone.

“My approach to semaglutide prescribing starts with a thorough evaluation, not a quick questionnaire. I want to understand each patient's metabolic health, medication history, and goals before we choose a medication and dose strategy. That level of individualization is what separates a medical weight loss program from an online prescription mill.”

Brittanie Lane, NP Nurse Practitioner

Nutrition and Exercise While on Semaglutide

Semaglutide creates a window of opportunity. By reducing appetite and cravings, it allows you to make dietary changes that may have felt impossible before. The key is using this window wisely by establishing eating and exercise patterns that you can sustain long-term.

Protein prioritization: Adequate protein intake is critical during weight loss to preserve lean muscle mass. We recommend aiming for 0.7 to 1.0 grams of protein per pound of lean body mass daily. Protein should be the foundation of every meal, as it also supports satiety and helps prevent the muscle loss that can accompany rapid weight reduction.

Hydration: Semaglutide's effects on gastric emptying and the common side effects of nausea and constipation make hydration especially important. Aim for at least 64 ounces of water daily, and more if you are physically active.

Meal structure: Eating smaller, more frequent meals (3 meals and 1 to 2 snacks) can help manage nausea and ensure adequate nutrient intake. Avoid large, heavy meals that sit in the stomach too long. Focus on lean proteins, vegetables, whole grains, and healthy fats.

Exercise: Resistance training (weight lifting, bodyweight exercises, resistance bands) is particularly important during GLP-1 therapy to maintain muscle mass. Aim for at least 2 to 3 resistance training sessions per week. Moderate cardiovascular exercise (walking, cycling, swimming) 3 to 5 times per week supports cardiovascular health and enhances weight loss. Start gradually if you are new to exercise and increase intensity over time.

Some patients find that IV hydration therapy helps manage the dehydration and fatigue that can accompany the early adjustment period, particularly if nausea makes oral hydration challenging.

What Happens When You Stop Semaglutide

This is perhaps the most important section of this guide, and it is the one most often glossed over by online prescribers. The STEP 4 trial data is clear: patients who discontinue semaglutide regain approximately two-thirds of their lost weight within one year of stopping the medication.

This weight regain is not a failure of willpower. It reflects the underlying biology of obesity. When you lose weight, your body responds with compensatory mechanisms designed to restore your previous weight. Hunger hormones (ghrelin) increase, satiety hormones decrease, metabolic rate drops, and your brain becomes more responsive to food cues. These changes can persist for years after weight loss, regardless of the method used to lose the weight.

Semaglutide counteracts these compensatory mechanisms while you are taking it. When you stop, those mechanisms reassert themselves. This is why obesity is increasingly recognized as a chronic condition that may require ongoing management, similar to how blood pressure medication manages hypertension.

That said, not every patient will regain all lost weight, and there are strategies to minimize regain:

• Gradual tapering: Rather than stopping abruptly, a slow dose reduction (from 2.4 mg to 1.7 mg, then to 1.0 mg over several months) may ease the transition and allow your body to adjust more gradually.
• Established habits: Patients who have genuinely adopted sustainable nutrition and exercise habits during treatment are better positioned to maintain their weight loss. The medication creates the window; the habits sustain the results.
• Maintenance dosing: Some patients benefit from staying on a lower maintenance dose (0.5 or 1.0 mg weekly) rather than discontinuing entirely. This approach may provide enough appetite regulation to prevent significant regain at a lower cost and side effect burden.
• Metabolic support: Optimizing thyroid function, managing stress, ensuring adequate sleep, and addressing hormonal imbalances can support metabolic health and reduce regain risk.
• Ongoing monitoring: Regular check-ins with your provider allow for early intervention if weight begins to trend upward after discontinuation.

Cost and Practical Considerations

Cost is a significant factor for most patients considering semaglutide. The retail price of brand-name Wegovy can exceed $1,300 per month without insurance. Insurance coverage varies widely, and many plans exclude weight loss medications or impose strict prior authorization requirements.

Compounded semaglutide, prepared by licensed compounding pharmacies, has emerged as a more affordable alternative. Compounded formulations can cost $300 to $600 per month depending on the dose and pharmacy. It is important to note that compounded semaglutide is not FDA-approved and is not subject to the same regulatory oversight as brand-name products. However, when sourced from a reputable 503B outsourcing facility that follows cGMP (current Good Manufacturing Practice) standards, compounded semaglutide can provide a viable option for patients who cannot access or afford the brand-name product.

When evaluating cost, consider the total value of the program, not just the medication price. A program that includes provider visits, lab work, nutritional guidance, and body composition monitoring may cost more upfront but typically delivers better outcomes and safety than a low-cost, medication-only model.

At Allen Medical Aesthetics, we provide transparent pricing for our weight loss program and help patients understand all costs before treatment begins. We also offer guidance on insurance prior authorization when applicable.

How Allen Medical's Weight Loss Program Works

Our medical weight loss program at Allen Medical Aesthetics is designed to provide comprehensive, medically supervised care that goes beyond simply writing a prescription.

Every patient begins with a detailed medical evaluation, including a full health history, current medication review, body composition analysis, and comprehensive metabolic lab panel. This evaluation determines whether semaglutide, tirzepatide, or another approach is the best fit for your clinical profile and goals.

Once treatment begins, you receive regular follow-up appointments that include weight and body composition tracking, lab work review, side effect management, nutritional counseling, and dose adjustment as needed. Our providers are available between appointments for questions and concerns.

We also recognize that weight management does not exist in isolation. Many of our weight loss patients also benefit from hormone optimization, as hormonal imbalances can significantly impact metabolism, appetite, energy levels, and body composition. Addressing both weight and hormonal health simultaneously often produces outcomes that neither treatment achieves alone.

Our goal is not just a number on the scale. It is helping you achieve a sustainable, healthier body composition that improves your quality of life, your metabolic health, and your long-term wellness.